Restricted accessResearch articleFirst published online 2014-10
Induction of Mixed Chimerism Using Combinatory Cell-Based Immune Modulation with Mesenchymal Stem Cells and Regulatory T Cells for Solid-Organ Transplant Tolerance
Establishment of mixed chimerism is an ideal approach to induce donor-specific tolerance while expanding its potential in various clinical settings. Despite the developments in partial conditioning regimens, improvements are still needed in reducing toxicity and bone marrow transplantation-related complications. Recently, cell-based therapies, including mesenchymal stem cells (MSCs), have been incorporated in establishing noncytoreductive mixed chimerism protocols; however, its efficacy is only partial and shows reversed immunosuppressive properties. This study demonstrates a novel approach to induce mixed chimerism and tolerance through combinatory cell-based immune modulation (CCIM) of MSCs and regulatory T cells (Tregs). We hypothesize that the interaction between these cells may lead to greater inhibition of host immune responses. Compared with single cell therapy, CCIM induced a higher engraftment rate and robust donor-specific tolerance to skin allografts across full major histocompatibility complex barriers. These regulatory effects were associated with inhibition of natural killer cell cytotoxic activity, CD4+IL-17+ cells, memory B cells, plasma cells, and immunoglobulin production levels along with increased frequencies of CD4+Foxp3+ cells, IL-10-producing mature B cells, and myeloid-derived suppressor cells. Furthermore, CCIM was able to regulate mortality in a graft-versus-host disease model through reciprocal regulation of Treg/Th17. Taken together, we suggest CCIM as a clinically applicable strategy for facilitating the induction of mixed chimerism and permanent tolerance.
Get full access to this article
View all access options for this article.
References
1.
CopelanEA. (2006). Hematopoietic stem-cell transplantation. N Engl J Med, 354:1813–1826.
2.
WelniakLA, BlazarBR and MurphyWJ. (2007). Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol, 25:139–170.
3.
PilatN and WekerleT. (2010). Mechanistic and therapeutic role of regulatory T cells in tolerance through mixed chimerism. Curr Opin Organ Transplant, 15:725–730.
4.
AsariS, ItakuraS, RawsonJ, ItoT, TodorovI, NairI, ShintakuJ, LiuCP, KandeelF and MullenYS. (2011). Mesenchymal stem cells facilitate mixed hematopoietic chimerism induction and prevent onset of diabetes in nonobese diabetic mice. Pancreas, 40:846–854.
5.
PilatN, BaranyiU, KlausC, JaeckelE, MpofuN, WrbaF, GolshayanD, MuehlbacherF and WekerleT. (2010). Treg-therapy allows mixed chimerism and transplantation tolerance without cytoreductive conditioning. Am J Transplant, 10:751–762.
6.
ItakuraS, AsariS, RawsonJ, ItoT, TodorovI, LiuCP, SasakiN, KandeelF and MullenY. (2007). Mesenchymal stem cells facilitate the induction of mixed hematopoietic chimerism and islet allograft tolerance without GVHD in the rat. Am J Transplant, 7:336–346.
7.
MarigoI and DazziF. (2011). The immunomodulatory properties of mesenchymal stem cells. Semin Immunopathol, 33:593–602.
8.
WuKH, WuHP, ChanCK, HwangSM, PengCT and ChaoYH. (2012). The role of mesenchymal stem cells in hematopoietic stem cell transplantation: from bench to bedsides. Cell Transplant, 22:723–729.
9.
KimEJ, KimN and ChoSG. (2013). The potential use of mesenchymal stem cells in hematopoietic stem cell transplantation. Exp Mol Med, 45:e2
10.
BluestoneJA. (2005). Regulatory T-cell therapy: is it ready for the clinic?. Nat Rev Immunol, 5:343–349.
11.
TangQ, BluestoneJA and KangSM. (2012). CD4(+)Foxp3(+) regulatory T cell therapy in transplantation. J Mol Cell Biol, 4:11–21.
12.
RubtsovYP, NiecRE, JosefowiczS, LiL, DarceJ, MathisD, BenoistC and RudenskyAY. (2010). Stability of the regulatory T cell lineage in vivo. Science, 329:1667–1671.
13.
JooSY, ChoKA, JungYJ, KimHS, ParkSY, ChoiYB, HongKM, WooSY, SeohJY, ChoSJ and RyuKH. (2010). Mesenchymal stromal cells inhibit graft-versus-host disease of mice in a dose-dependent manner. Cytotherapy, 12:361–370.
14.
BurrSP, DazziF and GardenOA. (2013). Mesenchymal stromal cells and regulatory T cells: the Yin and Yang of peripheral tolerance?. Immunol Cell Biol, 91:12–18.
15.
RaJC, ShinIS, KimSH, KangSK, KangBC, LeeHY, KimYJ, JoJY, YoonEJ, ChoiHJ and KwonE. (2011). Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans. Stem Cells Dev, 20:1297–1308.
16.
ChoiEW, ShinIS, ParkSY, ParkJH, KimJS, YoonEJ, KangSK, RaJC and HongSH. (2012). Reversal of serologic, immunologic, and histologic dysfunction in mice with systemic lupus erythematosus by long-term serial adipose tissue-derived mesenchymal stem cell transplantation. Arthritis Rheum, 64:243–253.
17.
AggarwalS and PittengerMF. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood, 105:1815–1822.
18.
GrinnemoKH, ManssonA, DellgrenG, KlingbergD, WardellE, DrvotaV, TammikC, HolgerssonJ, RingdenO, SylvenC and Le BlancK. (2004). Xenoreactivity and engraftment of human mesenchymal stem cells transplanted into infarcted rat myocardium. J Thorac Cardiovasc Surg, 127:1293–1300.
19.
ChoSG, ShutoY, SodaY, NakazakiY, IzawaK, UchimaruK, TakahashiS, TaniK, TojoA and AsanoS. (2004). Anti-NK cell treatment induces stable mixed chimerism in MHC-mismatched, T cell-depleted, nonmyeloablative bone marrow transplantation. Exp Hematol, 32:1246–1254.
20.
PrigozhinaTB, ElkinG, KhitrinS and SlavinS. (2004). Depletion of donor-reactive cells as a new concept for improvement of mismatched bone marrow engraftment using reduced-intensity conditioning. Exp Hematol, 32:1110–1117.
21.
YiT, ChenY, WangL, DuG, HuangD, ZhaoD, JohnstonH, YoungJ, TodorovI, et al. (2009). Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood, 114:3101–3112.
22.
PrigozhinaTB, ElkinG, KhitrinS and SlavinS. (2008). Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation. Exp Hematol, 36:1750–1759.
23.
ItescuS, BurkeE, LietzK, JohnR, ManciniD, MichlerR, RoseE, OzM and EdwardsN. (2002). Intravenous pulse administration of cyclophosphamide is an effective and safe treatment for sensitized cardiac allograft recipients. Circulation, 105:1214–1219.
24.
SykesM. (2001). Mixed chimerism and transplant tolerance. Immunity, 14:417–424.
25.
WekerleT, NikolicB, PearsonDA, SwensonKG and SykesM. (2002). Minimal conditioning required in a murine model of T cell depletion, thymic irradiation and high-dose bone marrow transplantation for the induction of mixed chimerism and tolerance. Transpl Int, 15:248–253.
26.
GracaL, DaleyS, FairchildPJ, CobboldSP and WaldmannH. (2006). Co-receptor and co-stimulation blockade for mixed chimerism and tolerance without myelosuppressive conditioning. BMC Immunol, 7:9
27.
StarzlTE, DemetrisAJ, MuraseN, IldstadS, RicordiC and TruccoM. (1992). Cell migration, chimerism, and graft acceptance. Lancet, 339:1579–1582.
28.
EggenhoferE, BenselerV, KroemerA, PoppFC, GeisslerEK, SchlittHJ, BaanCC, DahlkeMH and HoogduijnMJ. (2012). Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol, 3:297
29.
Vukmanovic-StejicM, ZhangY, CookJE, FletcherJM, McQuaidA, MastersJE, RustinMH, TaamsLS, BeverleyPC, MacallanDC and AkbarAN. (2006). Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo. J Clin Invest, 116:2423–2433.
30.
FritzschingB, KorporalM, HaasJ, KrammerPH, Suri-PayerE and WildemannB. (2006). Similar sensitivity of regulatory T cells towards CD95L-mediated apoptosis in patients with multiple sclerosis and healthy individuals. J Neurol Sci, 251:91–97.
31.
ZhouX, Bailey-BucktroutSL, JekerLT, PenarandaC, Martinez-LlordellaM, AshbyM, NakayamaM, RosenthalW and BluestoneJA. (2009). Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol, 10:1000–1007.
32.
EngelaAU, BaanCC, PeetersAM, WeimarW and HoogduijnMJ. (2013). Interaction between adipose tissue-derived mesenchymal stem cells and regulatory T-cells. Cell Transplant, 22:41–54.
33.
XiaG, HeJ and LeventhalJR. (2008). Ex vivo-expanded natural CD4+ CD25+ regulatory T cells synergize with host T-cell depletion to promote long-term survival of allografts. Am J Transplant, 8:298–306.
34.
JoffreO, SantolariaT, CaliseD, Al SaatiT, HudrisierD, RomagnoliP and van MeerwijkJP. (2008). Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. Nat Med, 14:88–92.
35.
SudresM, NorolF, TrenadoA, GregoireS, CharlotteF, LevacherB, LatailladeJJ, BourinP, HolyX, et al. (2006). Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J Immunol, 176:7761–7767.
36.
HoogduijnMJ, Roemeling-van RhijnM, EngelaAU, KorevaarSS, MensahFK, FranquesaM, de BruinRW, BetjesMG, WeimarW and BaanCC. (2013). Mesenchymal stem cells induce an inflammatory response after intravenous infusion. Stem Cells Dev, 22:2825–2835.
37.
MurphyWJ, KumarV and BennettM. (1987). Acute rejection of murine bone marrow allografts by natural killer cells and T cells. Differences in kinetics and target antigens recognized. J Exp Med, 166:1499–1509.
38.
Le MoineA and GoldmanM. (2003). Non-classical pathways of cell-mediated allograft rejection: new challenges for tolerance induction?. Am J Transplant, 3:101–106.
39.
VilchesC and ParhamP. (2006). Do NK-cell receptors and alloreactivity affect solid organ transplantation?. Transpl Immunol, 17:27–30.
40.
MurphyWJ, KumarV and BennettM. (1987). Rejection of bone marrow allografts by mice with severe combined immune deficiency (SCID). Evidence that natural killer cells can mediate the specificity of marrow graft rejection. J Exp Med, 165:1212–1217.
41.
CudkowiczG and BennettM. (1971). Peculiar immunobiology of bone marrow allografts. II. Rejection of parental grafts by resistant F 1 hybrid mice. J Exp Med, 134:1513–1528.
42.
SpaggiariGM, CapobiancoA, AbdelrazikH, BecchettiF, MingariMC and MorettaL. (2008). Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood, 111:1327–1333.
43.
GhiringhelliF, MenardC, TermeM, FlamentC, TaiebJ, ChaputN, PuigPE, NovaultS, EscudierB, et al. (2005). CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med, 202:1075–1085.
44.
RedfieldRR, 3rd, RodriguezE, ParsonsR, VivekK, MustafaMM, NoorchashmH and NajiA. (2011). Essential role for B cells in transplantation tolerance. Curr Opin Immunol, 23:685–691.
45.
NoorchashmH, ReedAJ, RostamiSY, MozaffariR, ZekavatG, KoeberleinB, CatonAJ and NajiA. (2006). B cell-mediated antigen presentation is required for the pathogenesis of acute cardiac allograft rejection. J Immunol, 177:7715–7722.
46.
FillatreauS, SweenieCH, McGeachyMJ, GrayD and AndertonSM. (2002). B cells regulate autoimmunity by provision of IL-10. Nat Immunol, 3:944–950.
47.
MizoguchiA, MizoguchiE, TakedatsuH, BlumbergRS and BhanAK. (2002). Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity, 16:219–230.
48.
LenertP, BrummelR, FieldEH and AshmanRF. (2005). TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production. J Clin Immunol, 25:29–40.
49.
MauriC, GrayD, MushtaqN and LondeiM. (2003). Prevention of arthritis by interleukin 10-producing B cells. J Exp Med, 197:489–501.
50.
Shimabukuro-VornhagenA, HallekMJ, StorbRF and von Bergwelt-BaildonMS. (2009). The role of B cells in the pathogenesis of graft-versus-host disease. Blood, 114:4919–4927.
51.
ReichardtP, DornbachB, RongS, BeissertS, GuelerF, LoserK and GunzerM. (2007). Naive B cells generate regulatory T cells in the presence of a mature immunologic synapse. Blood, 110:1519–1529.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
